Literature DB >> 23357051

A novel KIT-deficient mouse mast cell model for the examination of human KIT-mediated activation responses.

Daniel Smrž1, Geethani Bandara, Shuling Zhang, Beverly A Mock, Michael A Beaven, Dean D Metcalfe, Alasdair M Gilfillan.   

Abstract

Activation of KIT, by its ligand, stem cell factor (SCF), results in the initiation of signal transduction pathways that influence mast cell survival and proliferation. Activating mutations in KIT have thus been linked to clonal MC proliferation associated with systemic mastocytosis. SCF also modulates MC function by inducing MC chemotaxis and by potentiating antigen (Ag)/IgE-mediated MC degranulation. Thus, mutations in KIT also have the potential to affect these processes in allergic and other mast cell-related diseases. Studies to determine how native and mutated KIT may modulate MC chemotaxis and activation have, however, been limited due to the lack of availability of a suitable functional MC line lacking native KIT which would allow transduction of KIT constructs. Here we describe a novel mouse MC line which allows the study of normal and mutated KIT constructs. These cells originated from a bone marrow-derived mouse MC culture out of which a rapidly dividing mast cell sub-population spontaneously arose. Over time, these cells lost KIT expression while continuing to express functional high affinity receptors for IgE (FcεRI). As a consequence, these cells degranulated in response to Ag/IgE but did not migrate nor show any evidence of potentiation of Ag/IgE degranulation in response to SCF. Retroviral transduction of the cells with a human (hu)KIT construct resulted in surface expression of huKIT which responded to huSCF by potentiation of Ag/IgE-induced degranulation and chemotaxis. This cell line thus presents a novel system to delineate how MC function is modulated by native and mutated KIT and for the identification of novel inhibitors of these processes. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23357051      PMCID: PMC3602326          DOI: 10.1016/j.jim.2013.01.008

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  39 in total

Review 1.  IgE, mast cells, basophils, and eosinophils.

Authors:  Kelly D Stone; Calman Prussin; Dean D Metcalfe
Journal:  J Allergy Clin Immunol       Date:  2010-02       Impact factor: 10.793

Review 2.  Development, migration, and survival of mast cells.

Authors:  Yoshimichi Okayama; Toshiaki Kawakami
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 3.  The tyrosine kinase network regulating mast cell activation.

Authors:  Alasdair M Gilfillan; Juan Rivera
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

4.  The phospholipase C gamma 1-dependent pathway of Fc epsilon RI-mediated mast cell activation is regulated independently of phosphatidylinositol 3-kinase.

Authors:  Christine Tkaczyk; Michael A Beaven; Saskia M Brachman; Dean D Metcalfe; Alasdair M Gilfillan
Journal:  J Biol Chem       Date:  2003-09-16       Impact factor: 5.157

5.  Non-apoptotic phosphatidylserine externalization induced by engagement of glycosylphosphatidylinositol-anchored proteins.

Authors:  Daniel Smrz; L'ubica Dráberová; Petr Dráber
Journal:  J Biol Chem       Date:  2007-02-05       Impact factor: 5.157

6.  Antigen and carbachol mobilize calcium by similar mechanisms in a transfected mast cell line (RBL-2H3 cells) that expresses ml muscarinic receptors.

Authors:  O H Choi; J H Lee; T Kassessinoff; J R Cunha-Melo; S V Jones; M A Beaven
Journal:  J Immunol       Date:  1993-11-15       Impact factor: 5.422

Review 7.  IgE and mast cells in allergic disease.

Authors:  Stephen J Galli; Mindy Tsai
Journal:  Nat Med       Date:  2012-05-04       Impact factor: 53.440

8.  Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens.

Authors:  Matthias Mayerhofer; Karoline V Gleixner; Andrea Hoelbl; Stefan Florian; Gregor Hoermann; Karl J Aichberger; Martin Bilban; Harald Esterbauer; Maria-Theresa Krauth; Wolfgang R Sperr; Jack B Longley; Robert Kralovics; Richard Moriggl; Jacques Zappulla; Roland S Liblau; Ilse Schwarzinger; Veronika Sexl; Christian Sillaber; Peter Valent
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

9.  Kit and FcepsilonRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells.

Authors:  Thomas R Hundley; Alasdair M Gilfillan; Christine Tkaczyk; Marcus V Andrade; Dean D Metcalfe; Michael A Beaven
Journal:  Blood       Date:  2004-06-24       Impact factor: 22.113

10.  Mast cell chemotaxis - chemoattractants and signaling pathways.

Authors:  Ivana Halova; Lubica Draberova; Petr Draber
Journal:  Front Immunol       Date:  2012-05-25       Impact factor: 7.561

View more
  4 in total

1.  SCF/C-KIT signaling modulates tryptase expression in acute myeloid leukemia cells.

Authors:  Jingchun Jin; Yan Li; Yue Wang; Pingping Wang; Yazhu Wang
Journal:  Int J Hematol       Date:  2014-05-08       Impact factor: 2.490

2.  Evidence for a novel Kit adhesion domain mediating human mast cell adhesion to structural airway cells.

Authors:  Kevin C Gough; Ben C Maddison; Aarti Shikotra; Elena P Moiseeva; Weidong Yang; Shila Jarvis; Peter Bradding
Journal:  Respir Res       Date:  2015-07-15

3.  Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production.

Authors:  Araceli Tobío; Geethani Bandara; Denise A Morris; Do-Kyun Kim; Michael P O'Connell; Hirsh D Komarow; Melody C Carter; Daniel Smrz; Dean D Metcalfe; Ana Olivera
Journal:  Haematologica       Date:  2019-04-04       Impact factor: 9.941

4.  Regulation of Reactive Oxygen Species and the Antioxidant Protein DJ-1 in Mastocytosis.

Authors:  Do-Kyun Kim; Michael A Beaven; Joseph M Kulinski; Avanti Desai; Geethani Bandara; Yun Bai; Calman Prussin; Lawrence B Schwartz; Hirsh Komarow; Dean D Metcalfe; Ana Olivera
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.